Loading organizations...
Duality Biologics is a clinical-stage biotechnology company based in Suzhou, China, that develops next-generation antibody-drug conjugates and bispecific antibodies targeting oncology and autoimmune diseases. The organization advances a technology platform supporting an internal pipeline of nearly ten therapeutic candidates, several of which have reached the investigational new drug or clinical testing phases. To evaluate these novel modality drugs, the enterprise conducts global multiregional clinical trials across twenty countries, enrolling a total of over 2,000 patients worldwide. Supported by a $90 million Series B venture capital financing round, the firm recently transitioned to public markets by listing on the Hong Kong Stock Exchange in 2025. The business generates research and development revenue through strategic global partnerships and backing from notable industry entities, including BioNTech, 3SBio, and LAV. Duality Biologics was founded in 2020 by Dr. John Zhu.
Duality Biologics has raised $90.0M across 1 funding round.
Duality Biologics has raised $90.0M in total across 1 funding round.
Duality Biologics has raised $90.0M in total across 1 funding round.
Duality Biologics's investors include Yi Shi, Green Pine Capital Partners, Huagai Capital, NRL Capital, Oriza Holdings, WuXi Biologics, Yunion Healthcare Ventures.
Duality Biologics has raised $90.0M across 1 funding round. Most recently, it raised $90.0M Series B in May 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 19, 2021 | $90M Series B | YI SHI | Green Pine Capital Partners, Huagai Capital, NRL Capital, Oriza Holdings, WuXi Biologics, Yunion Healthcare Ventures | Announced |
